{"slug":"ara-290-postherpetic-neuralgia","title":"ara 290 postherpetic neuralgia","body":"## Regeneration vs degeneration — where this fits\n\npostherpetic neuralgia represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether ara-290 mechanisms address underlying repair deficits.\n\n## What is known\n\nStudied for nerve repair and small-fiber regeneration in neuropathy models.\n\nTarget condition: postherpetic neuralgia.\nBody system: peripheral nerve.\n\n## Logic chain\n\n1. ara-290 studied for nerve repair and small-fiber regeneration in neuropathy models..\n2. postherpetic neuralgia involves peripheral nerve dysfunction.\n3. If ara-290 reaches the affected tissue, it may shift the repair/breakdown balance.\n4. This chain is tested in animal or lab models only.\n\n## Parent peptide claims relevant here\n\n- ARA-290 is an 11-amino-acid peptide engineered from erythropoietin that selectively activates the innate repair receptor (IRR).\n- In phase 2 trials, ARA-290 reduced neuropathic symptoms and improved quality of life in sarcoidosis small fiber neuropathy patients.\n- ARA-290 treatment increased corneal nerve fiber density in sarcoidosis patients with initial reductions.\n- In rodent sciatic and spared nerve injury models, ARA-290 reduced allodynia in a β-common receptor-dependent manner.\n- Commercial vendors and clinics market this compound (17 commercial/clinic sources catalogued) — marketing material, not evidence.\n\n## Evidence tier\n\nPreclinical — animal and in vitro studies only. No published human trials for this specific combination.\n\n## What we do not know\n\n- Whether ara-290 reaches postherpetic neuralgia tissue at functional concentrations\n- Optimal dosing, route, and duration for this target\n- Interaction with standard-of-care treatments for postherpetic neuralgia\n- Long-term safety profile in this population\n\n## Safety note\n\nAll peptide use for postherpetic neuralgia is research-context only. Not medical advice. Consult a physician before any experimental compound.","register":"standard","tags":["peptide"],"category":null,"style":{},"claims":[{"id":"c_map_ara-290-postherpetic-neu","text":"Combinatorial mapping (transparent): ara-290 vs postherpetic-neuralgia — regen=0.717, degen=0.85, Δ=-0.133. Method: layer_relevance(0.75) × evidence_factor(0.85); catalog.degen_score for Postherpetic neuralgia.","section":"what_is_known","tier":"system"}],"sources":[],"prov":{"model":"grok/grok-4.3","action":"write"}}